Demant A/S (DEMANT) Earnings Call Transcript
February 3, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and welcome to the conference call covering Demant's 2025 annual results. I'm Peter Pudselykke, and I lead investor relations activities here at Demant. Joining me today is the usual team: our President and CEO, Søren Nielsen; our CFO, René Schneider; and Gustav Høgh from the IR team. During the call, we'll give a presentation, and after that we'll take Q&A. We expect this session to run no more than 1 hour in total. When we reach the Q&A, we kindly ask you to limit yourselves to 2 questions at a time so as many people as possible can ask a question. Before we dig into the presentation, please do pay notice to the disclaimer on slide number 2. With that, I'll go to slide number 3, where I'll pass the baton to Søren to kick off the presentation, please.
Thanks so much, Peter, and hello everyone. Today's agenda covers the key events of 2025, financial takeaways, then remarks about progress on sustainability, and further detail on the business area reviews — including, notably, the fourth quarter. After that, René will walk us through the group financials and also take us through the outlook and the initiatives aimed at improving profitability. Looking at 2025 overall at group level, we delivered 2% organic growth, 5% in local currencies. Acquisitions were of course a significant element, and currency headwind leaves us at 2% reported growth. The biggest expansion, you could say, is in Hearing Care, which is now the largest business area, as you can see on the business mix split. Gross profit rose 2%, though the margin was down, related to, I would say, Hearing Aids and to some extent Diagnostics, but we'll come back to that. EBIT fell 10% before special items, and free cash flow was down 11%. Key events in 2025: we acquired the KIND Group in Germany, closed the deal in December, and have 1 month in the books. It's one of the world's leading retailers, and with that we are significantly expanding our position globally, but in particular in Germany, to a number 1 in Hearing Care.
Back in October, we brought Oticon Zeal to a number of chosen markets, and that launch has generated substantial enthusiasm so far along with plenty of positive momentum that we'll carry into '26. Over the course of 2025, we reached agreements to sell off both EPOS and Oticon Medical, which aligns with our broader strategy of becoming a more focused hearing healthcare company. The hearing aid market during 2025 was weaker than usual, especially in the US, where overall market growth came in flat for 2025. Hearing Care posted a very solid performance — solid performance — particularly when you consider the global hearing aid market, while Hearing Aids and Diagnostics showed softer growth. All 3 business areas demonstrated stronger and improved performance in Q4. Key financial takeaways for the second half: group organic growth of 4% across the second half in total, a sequential gain over the first half driven by all 3 business areas; gross margin fell compared with second half '24 because of ASP headwinds in Hearing Aids plus a rising share of rechargeability — I'll come back to that, but the ASP headwind stems from channel and geography mix, as we sell more in countries and channels carrying a lower ASP and less in higher-priced markets such as the US; Diagnostics was also a minor drag on gross margin, coming from their product mix and some geography; OPEX rose 5% organically, but — as already guided for and expected — was flat sequentially from H1, still reflecting a cautious approach to cost expansion when we look at it sequentially.
That 5% is partly driven by a sizable holdback at the close of '24. Acquisitions contributed 5 percentage points of growth versus the second half of last year. EBIT before special items came in at 2.1, or 2.1 billion, hit negatively by exchange rate effects and by reduced operating leverage. So the EBIT margin before special items narrowed by 2.6 percentage points. Special items were Danish kroner minus 128 million. Cash flow from operations was strong at 2.3 million billion, with free cash flow of roughly 2 billion Danish kroner. On the outlook, René will go into more detail for '26: organic growth between 3% and 6%, EBIT before special items of 4.1 to 4.5 billion Danish kroner, and a continued pause on our share buyback so we can bring down group leverage. A quick word on sustainability achievements: we saw, as expected, an increase in improved lives by overcoming their hearing loss, reaching 12 million, plus a growing number of tests in our own clinics after the expansion of that. Looking at our main, or 3 main, sustainability goals under the respect for the planet headline: on the planet decrease in our Scope 1 and 2 greenhouse gas emissions, we've now reached a 16% reduction against baseline, with a target of 46% by 2030; gender diversity in top-level management stands at 33%, 1 in 3, with the aim of exceeding 35% by 2030; and the share of people who have read and understood it, out of those for whom it's relevant, should be 100% by 2030 — and you could say basically already tomorrow if at all possible, and we're almost there.
Okay, on the business area review: the hearing aid market in '25 has certainly been unusual, and the fourth quarter—which is the new release—is no exception. We've observed high unit growth, and that's across all units in Europe, though it's mainly driven by the NHS in the UK, the National Health Service, which has seen strong growth partly from expanding inventory levels, and so on; and then France is also showing high growth as expected because of the annuitization of the reform. If we exclude the NHS and France, unit growth in Europe was 3%. In Germany specifically, growth was down year over year. North America had a sequential slowdown from 2 quarters at 2% growth to 0, finishing the year at 1. The US, or Canada, saw good growth, offset by flat growth in US commercial and slightly negative growth in the VA. The rest of the world delivered growth: Australia was positive, while Japan had minimal growth; China improved sequentially; and we estimate that several emerging markets had good growth. On ASP again—we normally assume a flat ASP, but there's no doubt that with the geographic mix and channel mix this year and in the fourth quarter as well, we estimate a negative impact on ASP—it isn't exact science, but at least in the area of a percentage points.
We estimate the global hearing aid market grew only about 2% in value for the year. On Hearing Aids in the fourth quarter: organic growth in Q4 also improved, even with weakness in the US market and share loss in the US. The primary place where we've been losing share in the US is still a large retailer where the count of providers or suppliers has been expanded. We launched Oticon Zeal in selected European markets, and that has generated excitement and a shift in momentum across these 4 countries. We've truly seen Zeal boost sales overall in these markets as well, though the effect on the total group level in the fourth quarter was limited, simply given the size of these 4 countries and their potential. Although Germany is a large country, the premium market there isn't that big, so again, it doesn't move the financials all that much. It does some, of course, but not that much in the fourth quarter. Unit growth was very solid, accounting for all market share gains in units across several key markets, I'd say almost everywhere with the main exception being the US. ASP was negative, as I mentioned, because of geography and channel mix changes.
Turning to Europe: France, the UK and Germany — every one of those is a major market, and we saw solid growth there. Canada also delivered a strong showing. As I mentioned, US growth came in negative. Japan and South America both grew nicely, and Asia excluding China was fairly broad-based as well; China, I'd still describe as market-related. On the Oticon Zeal rollout, a few additional remarks. We brought it to market in Europe — Germany, Switzerland, the UK and Denmark — and the takeaway is identical in each: hearing care professionals and end users alike regard it, without dispute, as a new and highly innovative concept. It genuinely helps end users make the decision to move forward and give it a try, with fewer hurdles in the way. Among first-time users, uptake has been viewed very favorably. It also boosts sales across the rest of our portfolio, since it opens the door to new customers. Say an end user has tried a Zeal and is pleased with the sound quality and the quality of the instrument, yet for some reason doesn't go on with it — or would rather continue with an in-ear, perhaps because of a comfort issue or the ear canal doesn't work — then fitting an Intent is the natural move, since you get more or less exactly the same sound quality and something the person just liked.
We are seeing incremental sales from customers who previously did not engage much with us, and we have also observed a limited degree of cannibalization among existing customers who have adopted Zeal. That is the finding across the 4 markets. I think we have also been transparent that this sits only at a premium price point and that in some markets we have raised pricing considerably relative to Intent, and up to now the price has been accepted and it has not stopped us from generating excitement and driving sales. Having said that, it is a premium price point. These are premium-category products, but it clearly also leads some people to spend more than they would have imagined had they needed to choose a receiver-in-the-ear instrument, where more options exist across various price points. I also believe we can say that you really cannot ask, okay, what is the potential and what is the share in the in-ear market, because that is not the way people, particularly first-time users, think about hearing aids. They will examine what is on offer at the table and select the one they find most appealing.
It's clear that first-time users find this far more appealing than using a conventional RITE device. Overall, these are strong results, and we're carrying that momentum into '26, where we've already launched in the US, where we'll launch in Canada this coming weekend, and where we'll launch in France in early March, followed by all the other significant and major markets. Germany will also step up its activities considerably in the first quarter to ensure a full rollout there, which wasn't the situation at the initial launch. Moving on — and again, without opening that discussion just yet — when we say there's still something ahead of us, it's because this remains a sequential launch; we have to go market by market to make sure we start off on the right foot. Of course, with the US market having been the most muted and holding big premium potential, it also depends to some degree on how the market evolves. Perhaps Zeal can help generate fresh excitement and interest among end users, though I'd say some uncertainty remains around that, which I'm sure René will address.
Our portfolio keeps growing. In Q1 as well, we’re launching devices built on our newest technology that use disposable batteries — still significant in certain channels and geographies — and we’re also adding a new option within part of the pediatric lineup. All of these new products deliver the latest and greatest sound quality and connectivity comparable to Zeal, and we’re getting very good feedback there too on the newest technology, which is also connectivity technology, and that’s available in Oticon Intent as well. Hearing Care in Q4: a solid performance in a hearing aid market that was weaker than normal, with of course a strong tailwind from a month with KIND. In the quarter, 17% in local currencies, 5% organic, and across the geography, strong performance in Poland and a number of other mid-sized European markets, continued solid growth in France driven by the anniversary of the '21 reform, good organic growth in North America driven by continued improved performance in the US very positively, however, some negative development in Canada. Australia saw good growth, continuing improved momentum, and China also delivered good organic growth driven by an ASP tailwind from a continued better product mix. All in all, well done in Hearing Care in the fourth quarter. Diagnostics also came in strong in the fourth quarter, delivering organic growth of 8% in local currencies, clearly the best-performing quarter this year here.
Overall, we saw healthy adoption. The UK and Germany posted robust expansion, and we had solid results in a number of mid-sized markets. In the US and Canada, growth was strong as well, though it came from the service and consumable business — which, to return to gross margin, is somewhat lower in those areas. Australia achieved significant growth, mainly through instrument sales, while China remained affected by broadly soft markets, and there was also a bit of caution around growth in Asia overall. With that, I'll hand it over to you, René.
Thanks, Søren. Let's move through the financials. There's a bit of repetition here, so I'll keep it brief. For revenue in the second half year, we posted solid organic growth of 4%. Hearing Aids and Diagnostics both delivered good organic growth, and Diagnostics in particular showed improvement in the fourth quarter. Acquisitions added 3 percentage points to growth, while FX was a 4% headwind, mainly because of the decline of the US dollars. On gross profit, it rose 3% to 8.8 billion. Gross margin came in slightly lower than the second half of last year, and that decline was driven mainly by geography and channel mix changes in our Hearing Aids business, and we also saw some headwind in the Diagnostics business, partly affected by tariffs. Finally, FX development was also a slight headwind on the gross margin. On operating expenses and EBIT: we grew OPEX by 5% organically half-year over half-year, partly because of very low comparative figures since we pulled back on costs significantly in '24, and development has been flat sequentially from first half year into second half year, which reflects our continued focus on cost management.
Acquisitions contributed another 5 percentage points of growth to OPEX during the second half of '25, and once again, a weakening US dollar provided an offset here as well. Turning to EBIT, we finished the second half at 2.1 billion, hit by currency effects and by reduced operating leverage in Hearing Aids. The drop in EBIT came mainly from softer-than-usual growth across the hearing aid market overall and, for our part specifically, from losing market share in the US, largely because of lower sales to a large retailer. That brought the EBIT margin down to 18 percentage points. Special items for the period related to the KIND acquisition and a non-cash adjustment, totaling 128 million in H2. Cash flow remained very strong. Cash flow from operations in H2 was 2.3 billion, with free cash flow just under 2 billion. Once again, we keep generating very strong cash flow. Our capital expenditure of 409 million is up versus the same period last year, mainly because of heavy investments in production facilities. Cash paid out for acquisitions came to 5.4 billion, and of course this mostly relates to the KIND acquisition that closed at the beginning of December.
During the second half of the year, no additional shares were bought under the share buyback program, and as previously disclosed, we finished the year at a total of 582 million. Turning to balance sheet items, net debt rose considerably. Once again, that is entirely attributable to the KIND acquisition. Exactly as we had anticipated, our gearing multiple closed the year at 3.4, above our medium- to long-term gearing target of 2 to 2.5. Deleveraging will be our priority, and we expect to get back to our medium- to long-term gearing target of 2 to 2.5 within 18 to 24 months after the 1st of December of '25. Net working capital rose modestly by 3%, and this again mainly reflects the effect of acquisitions added to the balance sheet, with things well under control here. So to sum up the financial key takeaways for the full year: we landed at 2% organic growth, once more driven by the weak overall hearing aid market; a gross margin contraction of 0.6 percentage point driven by weak market growth, particularly in the US, and ASP headwinds in Hearing Aids due to geography and channel mix changes.
For the entire year, operating expenses rose just 3% on an organic basis, reflecting the cost discipline we continue to apply; EBIT before special items came in at 3.96 billion, with an EBIT margin of 17.2%; special items totaled 128 million; and, as we just went through, we delivered strong cash flow, with 3.85 of cash flow from operations across the full year, free cash flow above 3 billion for the full year as well, and share buybacks of 582 million. That wraps up the quick walk-through of the financials, which brings us to the outlook section and the initiatives we've undertaken there. If we begin with some of the assumptions underlying our outlook — assumptions that, of course, point to the fact that we lack certainty on these matters, but we enter with an initial hypothesis. Naturally, the key assumption behind our outlook for the year is our projection that the global hearing aid market will grow 2% to 4% in 2026 in value, which is clearly a conservative assumption, sitting temporarily below our medium- to long-term assumption of 4% to 6%, and, of course, also low when viewed against the last decade, in which growth tracked exactly in line with that 4% to 6%.
We think it makes sense, and it's consistent with what we saw during the last quarter, to adopt a careful stance on the market as we head into the year, and that's what we're doing with the 2% to 4% for the market. We'll revisit that, but our belief is that Demant will, in every scenario, outgrow the market in '26. Another key assumption on the right-hand side is that as part of our '26 plans, we've kicked off a company-wide initiative aimed at precisely improving profitability and slowing cost growth, and specifically in certain areas leading to cost cuts. These initiatives will have a positive effect on EBIT before special items of roughly 250 million in '26. Because this is an initiative beginning now, we anticipate that most of that effect will show up in the second half year, which explains why, for '26, we see EBIT weighted more than usual toward the second half year. Product launches, too, affect how EBIT is phased in '26 — this is an important point. We've witnessed a considerable drop in the US dollar especially, but in other currencies as well, and we anticipate a negative FX effect on EBIT of 200 million relative to '25, with that effect split evenly between H1 and H2.
For '26, we anticipate the KIND Group will deliver 300 million in EBIT before special items. That matches what we communicated previously, and on tariffs we foresee only a limited effect on the group — 25 million within our Diagnostics business, which is also nothing new. To sum up on special items, the particular items we see going into the accounts for '26 now come to 325 million in total, and 125 of that ties to the integration costs we already announced in connection with the KIND acquisition. On top of that, we add a further 200 million for the anticipated restructuring as well as adjustments to the organization and its size under this cost reduction initiative. So here we have 200 million of one-off costs, and 325 all in all. Those are among the core assumptions. Building on that, if you look at some of the components in a more visual schematic form on the graph to the right, our starting point is the EBIT for the full year '25 of 3.96. From there, we have to subtract the 200 million representing the FX headwind in '26. That takes us to an FX-adjusted EBIT for '25 of 3.76.
So to that, following the guidance we've laid out here, we'd add the incremental contribution from KIND, and that represents 11 months of EBIT. Just as a reminder, we had 1 month in '25, so this is 11 months of the 300 million: 275. Then we need to add the organic portion of our business, which takes in the cost-savings initiatives mentioned earlier that we're confident will deliver 250 million of savings on the OPEX line, and on top of that, whatever additional organic profitability impact we see in the rest of the group. That adds up to an EBIT outlook of 4.1 to 4.5 billion. It's important to note here that the backdrop for this outlook is, of course, a starting point of a market assumption of 2% to 4%. In our plans we aim to grow above that, at 3% to 6%, essentially taking market share in all scenarios. In that light, you can of course say that the 4.1, the lower end of this guidance, reflects a very, very conservative scenario in which the market is, of course, at the conservative end of the already conservative outlook here, and also that our market share gain is modest, but still there.
That gives us our starting point for the year, and we're comfortable with it. Finally, a few additional remarks about the profitability initiatives. I mentioned earlier the 250 million effect in '26, but this program spans 2 years and, from '28 onward, will deliver roughly 500 million in cost savings to the group. We also announced today that we estimate approximately 700 people globally at Demant will be affected in '26, with 150 of them based in Denmark. The related costs, which we recognize under special items, come to 200 million in '26 plus another 100 million in '27 — both, of course, one-off in nature — while the expected savings will be structural and permanent. To sum up, in total this brings us to our outlook for '26: organic growth of 3% to 6%; EBIT of 4.1 to 4.5 billion; the share buyback is expected to be paused through '26 as we focus on deleveraging; and for modeling purposes, we estimate acquisitive growth of 8%, FX growth of minus 2%, and special items of minus 325 million, along with an effective tax rate of 23%. With that, we'll hand over to Q&A, please.
We’re moving into the Q&A portion now. If you’d like to ask something, press star followed by one on your touch-tone phone. When you’re on a speakerphone, lift the handset first, then press your keys. Should your question get answered at any point and you want to pull it, just press star then two. We’ll take a brief pause right now. Today’s opening question is from Richard Felton at Goldman Sachs. Go ahead, please.
Hello, and thank you very much for taking my questions. I have just two, if I may. First, regarding your guidance: the midpoint of the organic growth guidance does imply growing ahead of the market in 2026. You said you expect to do that in all scenarios. My question is, what is it that gives you that confidence in outperforming the market in 2026 in all scenarios? Then, secondly, René, I wanted to follow up on your comments on EBIT phasing linked to product launches. Is that due to the phasing of the Zeal rollout, or is there anything else to consider as you think about EBIT phasing? Thank you.
I'll take the first one, and René can speak to the other. That's within Hearing Aids, where market share gains are the primary driver. Of course, we will also see share gain come from boosting our position in the German market following the KIND acquisition, but the main thing is the momentum that I'm confident Zeal will generate once we have the full rollout and all channels at the end are opened. And of course, we continue to have a strong launch program for the rest of this year and next year — it's the confidence in all of that which keeps us firm on market share gains across all scenarios.
Regarding how EBIT is phased, two things are worth keeping in mind. First, our cost savings initiative will have a modest impact in Q2, but mostly it will show up in Q3 and Q4 — that's the first factor. Second, Zeal is being rolled out gradually, so naturally it will contribute during the first half of the year, yet in H2 it will deliver the benefit of a full half-year.
Understood — thanks.
The following question is from Martin Parkhøi at SEB. Please go ahead.
Yes, thanks a lot. I've just got a couple of questions. First, coming back again to that 3% to 6% organic growth guidance, could you give a bit more detail on what organic growth you're assuming across the divisions? We saw Diagnostics have a bit of a dream run in the fourth quarter, but what are you assuming for Diagnostics in '26? Then, of course, also the split between wholesale and Hearing Care on organic growth? I understand that KIND will of course add acquisitive growth. Then second, just René, on gross margin expectations for 2026 — 2025 was not a pretty year. What have you assumed for gross margin development in 2026 on an underlying basis, and, of course, also say how much KIND contributes in that context overall?
Martin, let me take the first question quickly. Right now, I'd describe the organic growth opportunities as equal across all the businesses, and for modeling purposes, I'd spread them relatively evenly among the three.
Regarding gross margin, we do have our general guidance, you could say, of 76% to 77%. On an underlying basis, as you mentioned, you're probably at the lower end of that range, but thanks to the contribution from KIND, we're likely to see a gross margin at the higher end of that range.
I just want to follow up, Søren, regarding organic growth. I understand it isn't clear at this point whether Zeal will be part of VA starting 1st of May. Does the high end of your guidance factor in that scenario?
When it comes to individual channels, it's quite specific. In VA, we have a growing business going into '26, and we do everything we can so that Zeal can also be made available for veterans. We haven't reached that conclusion yet.
Thanks.
Our next question is from Hassan Al-Wakeel at Barclays. You have the floor.
Good afternoon, and thanks for taking my questions. First, regarding what you said about intense competition, can you help quantify how much Costco affected the quarter, and how you're incorporating that into your 2026 guidance? How would you describe share trends in the US commercial market, and are there any other unfavorable share dynamics you'd flag? Second, on margin guidance, I appreciate the weaker market, but can you help us understand the building blocks for a margin that is down year-over-year even with a benefit from the restructuring program in the second half? On your comment about launches, could you discuss how that would affect phasing and whether you're on track for a platform launch in 2026? Thank you.
I'll begin with the first question and the final one. Regarding any new launches, we don't make comments until they actually happen. I believe that tradition is familiar to all of you. All I can do is say again: in our view, we have a robust pipeline ahead of us for the upcoming year, and that includes the back half of this year. On US share trends: naturally you have visibility into VA, where following recent launches we've observed a slight dip for Oticon, though I'd say we've held up well on other fronts. With the large retailer, year-over-year we do see share declining after they broadened their supplier count, but things have been fairly steady since that shift. As for the independents, all I can tell you is the competition is extremely fierce. I can't rule out that some have been hesitating somewhat while waiting for Zeal, so I'd describe it as a slight sequential softening toward year-end, yet I'm confident and hopeful we'll recover now that Zeal has launched in the US market. That's what I'm able to address at this point.
On the margin side, for development in '26, obviously our starting assumption of market growth between 2% and 4% makes it challenging. That's, you could say, the fundamental headwind to margin that we're dealing with. Naturally, given this, our cost initiatives matter a great deal, since that's what gets us, you could say, at the midpoint of our guidance at least, to a flat EBIT margin in local currency, and anything beyond that would be margin expansion. Obviously, if we assume market growth of 2% to 4%, margin expansion, which isn't in line with our mid- to long-term, then margin expansion as such is a challenge, but at least at midpoint we're flat.
Thanks.
Our next question is from Julien Ouaddour at Bank of America. Go ahead, please.
Thanks a lot for taking my questions. There are two of them. The first concerns Zeal, where you described the feedback as pretty good. From what I understand, Zeal is the primary driver behind the share gains in '26, as you mentioned. Could you share a bit about which market share assumptions you've built into the '26 guidance for Zeal within the ITE category? I ask because we're seeing a competitor product performing quite well at the moment, and I believe another one of your competitors announced new ITE products just this morning. Also regarding Zeal, can you confirm whether it's already accretive to group margin and how the volume increase might affect profitability? A very quick second question is about the ASP. It declined 2% in '25. I think that's below your mid-term assumption. You're also experiencing intense competitive pressure right now. Do you see a need for some kind of price discounts in the RIC category until a new premium platform arrives as Intent gets old? What might that mean for pricing in H1 '26? Could it decline again? Thank you.
I'll begin with pricing, and then I'll come back to Zeal. When we look at ASP being lower, that comes down to a mix of channels and geographies. I think we still maintain a strong capacity to command meaningfully better pricing than a great many others, and most of the independent sector. No, I wouldn't point to Intent as something to sell off, since it ought not to be competitive. I'd also like to emphasize — perhaps circling back somewhat to Hassan's question about product launches — that we're extremely, extremely pleased with how Oticon Intent and Zeal are performing. This platform lets us deliver precisely these exceptionally high-performing products at sizes that are now unprecedentedly small. Zeal comes with full connectivity and with full AI-driven signal processing, and that is the reason Zeal enjoys such a strong reputation. It isn't the first in-ear, instant-fit style product anyone can make, but never before have you seen one with a feature list so complete that it stands fully comparable to any RIC. Going back to what I said at the outset as well: as we open new doors with Zeal, what we conclude from the first four markets is that we're also seeing Intent sales grow, because it is an equally very good product.
Zeal serves as a gateway into more sales overall, which is another reason the ASP impact of Zeal can’t be measured. Zeal arrives with a very strong ASP, and naturally, extra Zeal volume will raise ASP, with all else held equal. It carries a higher price than anything else in our lineup, yes, which is very positive for ASP. If we sell a great deal in the US and that market expands, our ASP will rise. The ASP effect in ’25 relates to geography and channel. Zeal, ITE category: no other products of ours provide the same features. Every new rechargeable in-ear product with connectivity is custom-made. These are what’s called in-canal, which are comparatively large devices that don’t deliver the same discreteness and invisibility as Zeal. If they were to get nearly as small as Zeal, connectivity isn’t present, and typically signal processing is also limited to accommodate a much smaller battery. The core element of Zeal is that it provides a much larger battery than any competitor in this size, and as a result, we maintain the full functionality we know from RICs, and that’s the strength. So you can’t simply measure share in the in-ear category, and I don’t see any new releases that challenge Zeal’s position.
Thanks, Søren. If I could just add one quick follow-up to what you said at the end there. Given all of that, should we be expecting Zeal to capture at least the global average market share in the ITE category?
Naturally, that figure will end up higher, since Zeal is going to pick up share beyond the in-ear segment. Obviously, you need to consider a certain upper portion of that market. Some markets may sell a great many relatively inexpensive in-ear products. If I set those aside, Zeal is going to win substantial share within the premium segment — taking it both from current in-ear options, which tend to be just the smaller, more cosmetically appealing ones, or mainly so, and from RIC products as well, since that is what a first-time user prefers.
Thanks for that, Søren — I appreciate it.
Anzhelika Bozinovic from BNP has the next question. Go right ahead.
Hello there, good afternoon, and thanks for taking my questions. Perhaps I could start once more with the guidance: could you share what you're assuming about the competitive landscape, particularly the competitor launches scheduled for H2, and more specifically within the ear category? Have you factored in the competitor launch that was announced this morning? My second question concerns the cost initiatives: would you mind providing further detail on the initiatives you're putting in place? Which areas and which regions would be impacted? Thank you very much.
We do, naturally, anticipate that rivals will keep trying to innovate and introduce new offerings into the market. There's nothing particular on our side in that regard, and what I witnessed today from one competitor is definitely something I'd note: yes, it is an in-ear product, but from what I understand, it sits in a lower price segment and offers nothing remarkable on the functionality front. Nothing I saw leads me to believe anything will alter Zeal's core competitiveness, distinctiveness, or level of innovation. I don't anticipate others bringing out products along those lines. The connection between the boxing technology and the capacity to achieve this compact form factor with all the features and benefits I just mentioned is very tight. No, I don't anticipate rivals being able to shut that gap in a brief period, and certainly not during this year. Cost programs: these are broad-based throughout the group. They appear essentially in every geography to differing degrees, naturally, based on our scale and footprint. They show up in every area: it isn't merely operations, it isn't merely R&D, it isn't merely any single one of those, it's essentially the whole company that we've examined. Naturally, in chosen areas, we can be even more resolute in our dedication to put money into R&D, into new products, into further growth of our hearing clinic footprint, and so on — all the elements that matter for growth.
We’ll identify places where—how should I put it—within the existing setup, there are ways to get things done that cost less.
Great, and just to add a quick follow-up to that first question: when it comes to the traditional RIC and the behind-the-ear product, have you factored any competitor launches into the guidance?
I don't have a particular assumption about exactly who will introduce what, except that over the last 12 months, we've seen a high number of launches from our competitors — new premium launches — which I would find less likely.
I appreciate that.
Our following question is from Martin Brenøe at Nordea. Go ahead, please.
Hello, Søren and René. Thanks for taking my questions. I have just two fairly straightforward ones. The first concerns the cost program, which is going to touch a large number of people across the organization—I'd simply like to hear about the timing of the cost reduction and the headcount reduction. My assumption is that we should expect this to be announced fairly quickly, and that the cost program will be more of a Q1 and Q2 program rather than back-ended, so as to avoid unnecessary uncertainty. That's my first question, and then I'll hold the second one for afterwards.
I'll move on that fast. Yes, regarding personnel and organizational adjustments, naturally, we want to act as swiftly as we can so the business can keep progressing. It invariably consumes time and energy. On the other hand, certain portions of this initiative focus on cost of goods sold, where our aim is to counter the increasingly pricey hearing aid types we must contend with. That requires some work from chosen R&D teams and others before they step in and before existing parts get used, if a redesign is involved. Some pieces of the program also have a longer timeline, yet the bulk and most of what concerns people will take place right here very shortly.
Thanks. Then my second question concerns value growth. So, thanks to '25 growing at roughly 2%, and part of that came from France, which has benefited from the replacement cycle, and also from the VA, with a fairly substantial price increase that will lap in May. One could say the market growth is perhaps somewhat inflated by those two channels and markets. I'm wondering, in your assumption going from 2% to 2% to 4%, where do you see that sequential step-up occurring if you look at the global market from here?
My take is that this would mean more balanced growth, or a different division in how the market expands between the US and the rest of the world. The US was essentially flat, while other regions outside it expanded more, and I'd say that is what underlies the 2% to 4%, where we assume a somewhat stronger US market. That, in turn, will provide support for global ASP. Thank you very much.
Veronika Dubajova from Citi has the next question. You have the floor.
Hello, everyone. Good afternoon, and thanks for taking my questions. There are two of them, and I should apologize—they're going to be a bit bigger picture. On the first one, I just want to press you a little on the EBIT guidance. I think if we build the bridge—adjusting for FX, adjusting for the cost savings, and adjusting, obviously, for the contribution from KIND—the guidance implies EBIT that's year-on-year minus 4% to plus 5%, against revenue growth of 3% to 6%. Even at the top end, there really isn't a huge amount of margin expansion. I guess my big picture question is: is this the new normal? If we end up in a market where growth is continuously challenged—not just in 2026, but let's say maybe even in 2027—should we assume it's going to be quite difficult, not just for you but for the industry as a whole, to drive earnings growth? I think that's kind of the question we've been having lots of discussions around. My second question—and I apologize for being forthright and blunt about this—but Intent is now 2 years old, you have normally followed 2-year launch schedules, and we are clearly not getting a platform in February this year.
Could you give us some assurance that the R&D process itself is sound — that this delay is something you're choosing to do on purpose, rather than a sign that something has gone wrong behind the scenes? With what happened with Zeal last year in mind, I think it would really help to hear how you're thinking about that. Thanks so much, guys.
Thanks a lot, Veronika. To some degree, you need to view the cost savings alongside what remains of the business. We'd still want to keep putting money into R&D, we'd still want to put money into expanding our footprint further, and that's the reason we're taking costs out in other areas. In my view, you have to look at those two things jointly. You can't simply remove the cost and then examine everything else. Across all scenarios, once you combine the two, EBIT is growing and margins are improving as well. The better we perform within the range, naturally. On the blunter question, no, I don't believe there's any problem with R&D. We've made it a priority to launch Zeal, since Zeal is achievable thanks to the platform we have, and we believe it carries big potential. Half of all users in the hearing aid industry are first-time users — roughly half — and that's a major opportunity there, and for some it's also the product they truly want even if they already own one. It carries a significant innovative element; our product roadmap is a deliberate choice and not a broken bike.
Understood — thanks so much, everyone.
Our next question is from Susannah Ludwig at Bernstein. Go right ahead.
Good afternoon, and thank you for taking my questions. There are two, please. First, regarding Zeal, you mentioned that it carries a higher ASP and will contribute positively to ASP. Could you clarify the effect on margins — specifically, whether its margin is also higher than the rest of your portfolio, given that higher ASP, or whether the different manufacturing process creates any negative impact on margins? Second, on the cost reduction program, could you share a bit more about which business areas you're targeting? For instance, in retail, should we expect any store closures as part of this program?
I appreciate that. Increasing premium sales is extremely beneficial for profitability. Zeal is designed to do exactly that and will expand our share of premium, so yes, without question. As we've mentioned previously, making Zeal costs more than producing a RIC, and if it were merely a swap with no meaningful price premium, that wouldn't hold. It outperforms classic in-ear instruments, it carries a higher price tag than RIC, and overall the profitability is solid. Raising premium sales, which is what we've observed so far in the markets where we've introduced it, is clearly a plus for profitability. Regarding the cost-reduction initiative, every business area has to contribute, though naturally the form and shape differ somewhat. Yes, we'd like to achieve the most on cost of goods sold, since that benefits everyone. We're being quite careful about our retail footprint and network, yet there are optimization opportunities too within a network where in certain regions, geographies, and areas down to individual cities, you might discover stores that aren't ideally located and don't generate the profit you'd expect. We'll examine the network as well, but it doesn't represent the bulk of the effort.
Thanks — that’s helpful.
Niels Granholm-Leth from DNB Carnegie has the next question. Go right ahead.
Thanks. Could you give us a bit more detail on how growth will be phased across this year? Should we expect the year to start off somewhat softer and finish stronger? And could you also discuss how long you anticipate keeping Zeal offered solely in your premium price version? Should we expect that to continue for the remainder of this year? Thank you.
Thank you very much. Growth is phased in a fairly standard way, with some pickup across the year as Zeal rolls out fully, of course, but not much difference between the first half and the second half if we hold it at that level. Zeal is premium only, which is, of course, also a deliberate choice. We believe it carries very substantial value potential, and so long as it remains unique and that potential is, as you might say, not yet fully tapped, we'll be cautious about adding further price points. Will that eventually happen? Yes, it will, but at present it's off the table.
Our following question is from Carsten Lønborg Madsen at Danske Bank. You have the floor.
Thanks a lot. Just one question remains for me, and it’s really a broader, high-level one — something investors keep asking us about a lot. Now that you’re bringing AI into hearing aids throughout the sector — you, your competitors — and we’re watching other AI players put massive CapEx in, is there something like a step change in R&D costs when it comes to developing the next hearing aid with AI capabilities, or is it more a continuation of the R&D budgets you’ve seen historically? That’s my question, I suppose.
Thanks for asking that. No, I wouldn't describe it as a step-up, though certainly, when you compare it with years ago, this is clearly an area where you're putting in more and more effort, and the complexity of what we need to develop keeps rising. That's another reason why a sustained commitment to investing in R&D matters so much. Coming back to our structural changes, those are part of ensuring we can keep investing in R&D, and much of that investment goes into AI-driven signal processing and into gaining the benefits of AI, you might say, across every aspect of operating a modern hearing aid system.
Thank you. One quick follow-up question: over the longer term, should we be expecting that you'll move into additional outside collaboration as a way of advancing the AI agenda?
I'd point to something we're doing at our research center as an illustration of that. The William Demant Foundation has provided a fairly substantial grant so that additional programs within the research community can be carried out under the umbrella of our Eriksholm Research Centre. And yes, we're also collaborating more with outside parties in order to build on this agenda.
Thanks.
Jack Reynolds-Clark from RBC Capital Markets has today's final question. Go right ahead.
Hello there, and thanks for taking the questions. I have two, please. The first one is about Zeal manufacturing. Could you remind us whether that is completely scaled at this point, or will it act as a limiter for the global launch? And then, how long will it take before you are fully ramped and have launched Zeal across all of your markets? The second question is whether the profitability initiative signals that you are more cautious about the timing of the recovery in market growth over the longer term than you were previously. Is it beyond 2026? Thank you.
I believe I've caught your questions—not entirely certain, but on the first one: no, we've done a sequential rollout so that we don't build up demand we aren't able to satisfy. That's the reason we go one market at a time, and we're comfortable with that approach, and we have solid production capacity and can also—or do have plans to—ramp up considerably, all fine. If anything, we're slightly ahead of the curve, I think that answers it.
Just to be sure, Jack, on your second question — is it about the fact that we see things differently regarding whether and when the market gets back to normal growth? Is that why we brought in the profitability initiatives?
You might argue that's our standard practice. What I'd say is we're speeding it up to guarantee we stay a robust business capable of ongoing investment in what our customers value most: R&D, solid service, and so on. Is there a connection? Yes, there is one. In my view, that acceleration has certainly taken place partly as a response to a persistent assumption that the market will stay weak.
That’s excellent. Thanks very much.
That brings our question-and-answer portion to a close. I'd now like to hand the conference back to the company in case it has any closing remarks.
Thanks, Operator, and many thanks to all of you for being with us today. I can see a few folks are still waiting in the queue—feel free to get in touch once the call wraps up, and we'll gladly follow up. As usual, we anticipate being out on the road over the next few weeks, and we very much look forward to seeing each of you whenever we're able to make it out your way. Enjoy the remainder of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Demant A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Demant A/S earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.